低分子肝素钙联合益气复脉注射液治疗重症肺源性心脏病合并呼吸衰竭患者的疗效分析  

Efficacy analysis of low molecular weight heparin calcium combined with Yiqi Fumai injection in the treatment of severe pulmonary heart disease patients with respiratory failure

作　　者：邱凯 张明妍[1] 张燕 QIU Kai;ZHANG Mingyan;ZHANG Yan(Sanming Hospital of Integrated Traditional Chinese and Western Medicine,Sanming 365000,China)

机构地区：[1]三明市中西医结合医院,365000

出　　处：《中国现代药物应用》2022年第14期9-12,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探索低分子肝素钙联合益气复脉注射液治疗重症肺源性心脏病合并呼吸衰竭患者的临床疗效。方法80例重症肺源性心脏病合并呼吸衰竭患者作为研究样本,以随机数字生成器生成方式将患者随机分为对照组与观察组,各40例。对照组开展常规治疗,观察组在对照组治疗基础上开展低分子肝素钙联合益气复脉注射液治疗。对比两组临床治疗效果、不良反应发生情况、治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]及血气指标[动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))]。结果观察组治疗总有效率95.00%高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗后,观察组FEV1(1.89±0.13)L、FVC(2.73±0.34)L、FEV1/FVC(71.47±3.42)%均优于对照组的(1.46±0.14)L、(2.32±0.35)L、(62.30±3.40)%,差异均有统计学意义(P<0.05)。治疗后,观察组PaO_(2)(89.15±5.56)mm Hg(1 mm Hg=0.133 kPa)、PaCO_(2)(58.59±3.32)mm Hg均优于对照组的(73.22±5.17)、(67.65±3.27)mm Hg,差异均有统计学意义(P<0.05)。观察组不良反应发生率2.50%低于对照组的15.00%,差异有统计学意义(P<0.05)。结论低分子肝素钙联合益气复脉注射液治疗重症肺源性心脏病合并呼吸衰竭患者效果较为显著,可有效改善患者临床症状,提升患者肺功能,优化血气指标,以促使患者生活质量提升,应用价值显著,值得应用推广。Objective To investigate the clinical efficacy of low molecular weight heparin calcium combined with Yiqi Fumai injection in the treatment of severe pulmonary heart disease patients with respiratory failure.Methods A total of 80 patients with severe pulmonary heart disease and respiratory failure were randomly divided into the control group and the observation group by means of a random number generator,with 40 cases in each group.The control group was treated with conventional treatment,and the observation group was treated with low molecular weight heparin calcium combined with Yiqi Fumai injection based on the treatment of the control group.Both groups were compared in terms of clinical effect,occurrence of adverse reactions,pulmonary function indexes[forced respiratory volume in the 1st second(FEV1),forced vital capacity(FVC),FEV1/FVC]and blood gas indexes[arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial pressure of oxygen(PaO_(2))]before and after treatment.Results The total effective rate 95.00%of the observation group was higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the FEV1(1.89±0.13)L,FVC(2.73±0.34)L,FEV1/FVC(71.47±3.42)%of the observation group were better than(1.46±0.14)L,(2.32±0.35)L,(62.30±3.40)%of the control group,and the differences were statistically significant(P<0.05).After treatment,the PaO_(2)(89.15±5.56)mm Hg(1 mm Hg=0.133 kPa)and PaCO_(2)(58.59±3.32)mm Hg of the observation group were better than(73.22±5.17)and(67.65±3.27)mm Hg of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 2.50%,which was lower than 15.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Low molecular weight heparin calcium combined with Yiqi Fumai injection has a significant effect in the treatment of severe pulmonary heart disease patients with respiratory failure,which can effectively impr

关 键 词：低分子肝素钙 益气复脉注射液 呼吸衰竭 重症 肺源性心脏病 

分 类 号：R541.5[医药卫生—心血管疾病] R563.8[医药卫生—内科学]